FDA approves skin cancer vaccine by...?
I think the market is somewhat overconfident, but still leans Yes because the leading melanoma vaccine candidate has reached positive phase 3 data and sits on a plausible FDA submission path before the deadline. My estimate is a moderately above-even chance of approval by the end of 2027, but not as high as the current market price implies.
Analysis
The main reason to lean Yes is that intismeran autogene has crossed the hardest scientific hurdle: it produced positive phase 3 results in resected melanoma when combined with pembrolizumab. That materially improves the odds that Moderna and Merck will seek FDA approval, and the event definition is broad enough that even a narrower melanoma label, a combination-regimen label, or an accelerated approval would all count. In other words, the market does not need a perfect, broad, first-line commercial launch for Yes to win; it only needs a qualifying FDA approval before the deadline.
At the same time, approval by December 31, 2027 is still a timing-sensitive bet rather than a pure science bet. A successful phase 3 result does not guarantee a smooth filing, review, and approval cycle, especially for a personalized therapy that depends on individualized manufacturing, potency, comparability, and operational consistency. Even if the sponsors move quickly, the FDA could require additional analyses, manufacturing clarifications, or extended follow-up that pushes the decision into 2028, which would make this market No despite eventual success. The gap between positive data and actual approval is often where markets overestimate speed.
The current market price of about 66.5% suggests traders think the regulatory path is fairly advanced, likely because this is not a speculative early-stage program anymore and because major companies with strong regulatory teams are involved. That said, the recent context also shows that the broader skin-cancer vaccine space still has no approved vaccine today, and other FDA actions in melanoma have been on non-vaccine therapies rather than on this specific product. So the evidence supports a real approval opportunity, but not one that is sufficiently de-risked to justify the high-60s without more concrete filing or review milestones.
My base case is that the program eventually reaches approval, but the deadline matters enough to keep the probability below the market. The biggest uncertainty is not whether the candidate has a credible clinical profile; it is whether the company can complete the regulatory package and whether the FDA can clear it on schedule. That makes this closer to a modest favorite than a strong one.
Arguments
For
- Arguments for Yes: The candidate has late-stage efficacy data, which is usually the strongest precursor to eventual FDA approval.
- Arguments for Yes: The event only requires any qualifying approval of the program, so even a limited melanoma label would satisfy the market.
Against
- Arguments against Yes: No actual FDA approval has occurred yet, so the market still depends on an uncertain regulatory sequence.
- Arguments against Yes: Personalized vaccines can face manufacturing and review challenges that are harder to resolve quickly than standard biologics.
Key drivers
- Positive phase 3 results substantially improve the odds that the sponsor will file for approval.
- The market definition is broad enough that a narrower or combination-based melanoma approval would still qualify.
- Personalized manufacturing and FDA review timing remain the main hurdles to approval before the deadline.
Risk factors
- The FDA could ask for additional data or CMC information that delays approval beyond 2027.
- Operational complexity for an individualized vaccine creates extra manufacturing and consistency risk.
- A positive trial does not guarantee the sponsors will obtain a filing, a priority review, or a decision in time.
Scenarios
Best case
The sponsors submit the application quickly, the FDA accepts it without major issues, and approval arrives in 2027 for a melanoma indication or another qualifying use.
Most likely
The program continues advancing toward approval, but the ultimate outcome hinges on whether regulatory and manufacturing steps finish fast enough to clear the FDA before year-end 2027.
Worst case
The FDA requests more data or manufacturing fixes, pushing the decision past the deadline or ending in a complete response that leaves the vaccine unapproved by 2027.
More from this day
- PoliticsKalshi23d
Will 3 mg THC beverages be federally legal to sell?
AI9%MKT92%Edge-83HypedA 3 mg THC beverage is very unlikely to remain federally legal to sell on Nov. 16, 2026 under the newly reported hemp rules. I put the Yes probability at 9%, with the market appearing heavily overpricing legalization persistence.
- economyPolymarketEnded
What will the median home value in the SF Metro area be on September 30?
AI16%MKT62%Edge-46HypedThe evidence strongly suggests the San Francisco metro median home value will remain above $1,176,000 on September 30, so the chance of a Yes outcome is low. The market price looks too optimistic for Yes given the recent price level and momentum.
- SportsKalshi37d
When will Bill Belichick leave North Carolina?
AI34%MKT69%Edge-35HypedI make Belichick’s chance of being out before Dec. 1, 2026 materially lower than the market suggests. The guaranteed contract and reported administrative support make an immediate exit possible but not the base case.